$FNCH
Finch Therapeutics Group, Inc. Stock $fnch

$fnch Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023009490 Filed on March 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$107.0K	$8.000K	$861.0K
YoY Change	-69.77%	-99.01%	-95.35%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.617M	$10.94M	$38.09M
YoY Change	2.26%	115.91%	79.34%
% of Gross Profit
Research & Development	$8.588M	$16.58M	$57.89M
YoY Change	-44.7%	12.01%	1.07%
% of Gross Profit
Depreciation & Amortization	$1.367M	$1.408M	$5.507M
YoY Change	2.7%	107.67%	139.33%
% of Gross Profit
Operating Expenses	$67.48M	$27.52M	$116.5M
YoY Change	170.64%	38.5%	48.32%
Operating Profit	-$67.38M		-$115.6M
YoY Change	174.1%		92.7%
Interest Expense	$425.0K	$259.0K	$252.0K
YoY Change	3169.23%	3137.5%	1045.45%
% of Operating Profit
Other Income/Expense, Net	-$25.00K	$486.0K	$947.0K
YoY Change	-292.31%	-1775.86%	-48.11%
Pretax Income	-$67.40M	-$27.01M	-$114.6M
YoY Change	174.35%	41.74%	97.12%
Income Tax	-$3.461M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$63.94M	-$27.01M	-$114.6M
YoY Change	160.26%	41.74%	97.12%
Net Earnings / Revenue	-59756.07%	-337600.0%	-13315.45%
Basic Earnings Per Share	-$1.33		-$2.40
Diluted Earnings Per Share	-$1.33	-$0.56	-$2.40
COMMON SHARES
Basic Shares Outstanding	48.14M	47.90M	47.69M
Diluted Shares Outstanding	48.09M		47.69M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.68M	$71.04M	$71.04M
YoY Change	-61.02%	-46.78%	-46.78%
Cash & Equivalents	$41.70M	$71.00M	$71.04M
Short-Term Investments
Other Short-Term Assets	$1.606M	$3.369M	$3.369M
YoY Change	-89.67%	-60.72%	-60.72%
Inventory
Prepaid Expenses
Receivables	$100.0K	$100.0K	$144.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$43.40M	$74.55M	$74.55M
YoY Change	-64.62%	-47.7%	-47.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.248M	$15.94M	$48.69M
YoY Change	-93.57%	-18.84%	97.21%
Goodwill		$0.00
YoY Change		-100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$4.232M	$6.800M
YoY Change	-95.6%	-13.72%	-5.2%
Total Long-Term Assets	$35.64M	$88.39M	$88.39M
YoY Change	-56.52%	6.73%	6.73%
TOTAL ASSETS
Total Short-Term Assets	$43.40M	$74.55M	$74.55M
Total Long-Term Assets	$35.64M	$88.39M	$88.39M
Total Assets	$79.04M	$162.9M	$162.9M
YoY Change	-61.37%	-27.7%	-27.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.553M	$1.097M	$1.097M
YoY Change	-46.42%	-70.64%	-70.64%
Accrued Expenses	$10.65M	$13.59M	$13.59M
YoY Change	-11.39%	22.97%	22.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.21M	$14.69M	$14.69M
YoY Change	-21.33%	-0.68%	-0.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$14.65M	$14.65M
YoY Change			209228.57%
Other Long-Term Liabilities	$0.00	$170.0K	$34.43M
YoY Change		2328.57%	604.42%
Total Long-Term Liabilities	$0.00	$14.82M	$49.08M
YoY Change		211657.14%	902.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.21M	$14.69M	$14.69M
Total Long-Term Liabilities	$0.00	$14.82M	$49.08M
Total Liabilities	$46.09M	$67.23M	$67.23M
YoY Change	85.52%	190.46%	190.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$339.6M	-$275.6M
YoY Change	83.0%	71.19%
Common Stock	$372.5M	$371.4M
YoY Change	1.96%	2.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$32.95M	$95.71M	$95.71M
YoY Change
Total Liabilities & Shareholders Equity	$79.04M	$162.9M	$162.9M
YoY Change	-61.37%	-27.7%	-27.7%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$63.94M	-$27.01M	-$114.6M
YoY Change	160.26%	41.74%	97.12%
Depreciation, Depletion And Amortization	$1.367M	$1.408M	$5.507M
YoY Change	2.7%	107.67%	139.33%
Cash From Operating Activities	-$13.38M	-$14.27M	-$74.85M
YoY Change	-47.82%	3.52%	11.5%
INVESTING ACTIVITIES
Capital Expenditures	$14.00K	$51.00K	$2.182M
YoY Change	-98.46%	-102.55%	-113.65%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$14.00K	-$51.00K	-$2.182M
YoY Change	-98.46%	-97.45%	-86.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-16.16M	52.00K	14.87M
YoY Change	-323280.0%	-25.71%	-87.51%
NET CHANGE
Cash From Operating Activities	-13.38M	-14.27M	-74.85M
Cash From Investing Activities	-14.00K	-51.00K	-2.182M
Cash From Financing Activities	-16.16M	52.00K	14.87M
Net Change In Cash	-29.55M	-14.27M	-62.16M
YoY Change	11.31%	-9.21%	-272.4%
FREE CASH FLOW
Cash From Operating Activities	-$13.38M	-$14.27M	-$74.85M
Capital Expenditures	$14.00K	$51.00K	$2.182M
Free Cash Flow	-$13.40M	-$14.32M	-$77.03M
YoY Change	-49.56%	21.54%	50.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02143
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001733257
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40227
CY2022	dei	Entity Registrant Name EntityRegistrantName	FINCH THERAPEUTICS GROUP, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3433558
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Inner Belt Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Somerville
CY2022	dei	City Area Code CityAreaCode	617)
CY2022	dei	Local Phone Number LocalPhoneNumber	229-6499
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	FNCH
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	76000000.0
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48144924
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71038000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133481000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	144000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	494000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3369000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8576000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	74551000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	142551000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15936000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19635000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32752000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5053000
CY2022Q4	fnch	In Process Research And Development InProcessResearchAndDevelopment	32900000
CY2021Q4	fnch	In Process Research And Development InProcessResearchAndDevelopment	32900000
CY2022Q4	us-gaap	Goodwill Goodwill	0
CY2021Q4	us-gaap	Goodwill Goodwill	18057000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2568000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2268000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4232000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4905000
CY2022Q4	us-gaap	Assets Assets	162939000
CY2021Q4	us-gaap	Assets Assets	225369000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1097000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3737000
CY2022Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	10161000
CY2021Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	9925000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3431000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1128000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14689000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14790000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3461000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3461000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14653000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34255000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4887000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	170000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7000
CY2022Q4	us-gaap	Liabilities Liabilities	67228000
CY2021Q4	us-gaap	Liabilities Liabilities	23145000
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48053596
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48053596
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47512182
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47512182
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	371304000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	363172000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275641000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160995000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	95711000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202224000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	162939000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	225369000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	861000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18532000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57893000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57279000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38088000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21238000
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	18057000
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2022	us-gaap	Restructuring Charges RestructuringCharges	2416000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0
CY2022	us-gaap	Operating Expenses OperatingExpenses	116454000
CY2021	us-gaap	Operating Expenses OperatingExpenses	78517000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-115593000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-59985000
CY2022	fnch	Gains Losses On Extinguishment Of Debt Includes Accrued Interest GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest	0
CY2021	fnch	Gains Losses On Extinguishment Of Debt Includes Accrued Interest GainsLossesOnExtinguishmentOfDebtIncludesAccruedInterest	1827000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	252000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	22000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	28000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	702000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-52000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	947000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1825000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-114646000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58160000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-114646000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58160000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-114646000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-58160000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.40
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.40
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47691632
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47691632
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39202086
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39202086
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-95718000
CY2021	fnch	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering	233053000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	115714000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3003000
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	10000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	181000
CY2021	fnch	Common Stock Warrants Exercised CommonStockWarrantsExercised	19303
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4161000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58160000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202224000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	141000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	148000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7844000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-114646000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	95711000
CY2022	us-gaap	Profit Loss ProfitLoss	-114646000
CY2021	us-gaap	Profit Loss ProfitLoss	-58160000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5507000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2301000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7844000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4161000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18057000
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	6926000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1808000
CY2022	fnch	Non Cash Interest Expense NonCashInterestExpense	167000
CY2021	fnch	Non Cash Interest Expense NonCashInterestExpense	0
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	28000
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2851000
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	913000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-350000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-540000
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	0
CY2021	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-61000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2529000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3217000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-656000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4689000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2259000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2261000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	237000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5435000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	50000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0
CY2022	fnch	Increase Decrease In Due To Related Parties Current Excluding Accounts Payable IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable	0
CY2021	fnch	Increase Decrease In Due To Related Parties Current Excluding Accounts Payable IncreaseDecreaseInDueToRelatedPartiesCurrentExcludingAccountsPayable	-266000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13631000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1931000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1006000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74851000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67133000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2182000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15983000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	62000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2182000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15921000
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	118576000
CY2022	fnch	Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts	0
CY2021	fnch	Proceeds From Underwriters Exercise Of Overallotment Option Net Of Underwriting Discounts And Commissions And Initial Public Offering Costs ProceedsFromUnderwritersExerciseOfOverallotmentOptionNetOfUnderwritingDiscountsAndCommissionsAndInitialPublicOfferingCosts	3049000
CY2022	fnch	Principal Payments On Capital Lease Obligation PrincipalPaymentsOnCapitalLeaseObligation	22000
CY2021	fnch	Principal Payments On Capital Lease Obligation PrincipalPaymentsOnCapitalLeaseObligation	27000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	289000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	171000
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	14738000
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	132000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2659000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14873000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119110000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-62160000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36056000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135965000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99909000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73805000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135965000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	741000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9000
CY2022	fnch	Payments For Proceeds From Operating Lease Liabilities PaymentsForProceedsFromOperatingLeaseLiabilities	-268000
CY2021	fnch	Payments For Proceeds From Operating Lease Liabilities PaymentsForProceedsFromOperatingLeaseLiabilities	-1434000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	381000
CY2022	us-gaap	Stock Issued1 StockIssued1	0
CY2021	us-gaap	Stock Issued1 StockIssued1	233053000
CY2022	fnch	Operating Right Of Use Assets Obtained In Exchange For New Operating Leases Upon Adoption Of Asc842 OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842	0
CY2021	fnch	Operating Right Of Use Assets Obtained In Exchange For New Operating Leases Upon Adoption Of Asc842 OperatingRightOfUseAssetsObtainedInExchangeForNewOperatingLeasesUponAdoptionOfAsc842	5965000
CY2022	fnch	Remeasurement Of Right Of Use Asset RemeasurementOfRightOfUseAsset	382000
CY2021	fnch	Remeasurement Of Right Of Use Asset RemeasurementOfRightOfUseAsset	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	37094000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	fnch	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	7736000
CY2021	fnch	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	0
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71038000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133481000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2767000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2484000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73805000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135965000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. NATURE OF OPERATIONS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Finch Therapeutics Group, Inc. (the “Company” or “FTG”) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (“Finch”) and Crestovo Holdings LLC (“Crestovo”) in September 2017 (the “Merger”), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (“Finch Holdings”). Finch and Finch Holdings are both wholly-owned subsidiaries of FTG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is a microbiome technology company with a portfolio of intellectual property and microbiome assets. The Company’s objectives are to realize the value of its intellectual property estate through licensing its technology to collaboration partners and enforcing its patents rights against infringing parties and, in certain cases, to generate additional data on selected product candidates through academic collaborations. The Company has an intellectual property estate including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company’s assets include CP101, an investigational, orally administered microbiome candidate designed for the prevention of recurrent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">C. difficile </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">infection (“CDI”), with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, the Company has developed a biorepository of strains and samples. In January 2023, the Company announced the decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets. This decision came after an assessment by the Company's management team and board of directors of multiple factors, including the Company's outlook for identifying a commercial partner, slower than anticipated enrollment in the PRISM4 trial, and broader sector trends in the biotechnology industry. The Company is currently in the process of winding down its development efforts and significantly scaling back its expenses, including by terminating vendor contracts and reducing headcount.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Until January 2023, the Company was a clinical-stage microbiome therapeutics company using its </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Human-First Discovery</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting microbiome disruption can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. The Company developed its </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Human-First Discovery</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> platform to use reverse translation to identify diseases of microbiome disruption and to design microbiome therapeutics that address them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to a number of risks, including risks related to government regulation, intellectual property and dependence on key personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has incurred recurring losses since its inception, including net losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">114.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">58.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> for the years ended December 31, 2022 and 2021, respectively. In addition, as of December 31, 2022, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">275.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. The Company expects to continue to generate operating losses for the foreseeable future as it attempts to realize the value of its intellectual property estate and other assets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On January 24, 2023, the Company announced its decision to discontinue its Phase 3 clinical trial of CP101 in recurrent CDI. As a result of this decision, the Company approved and implemented a restructuring plan (the "January 2023 Restructuring") (see Note 17). Also on January 24, 2023, the Company announced its decision to shift the Company’s business strategy to focus on realizing the value of the Company’s intellectual property estate and other assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company currently forecasts that its cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">71.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">as of December 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of issuance of the annual consolidated financial statements. However, due to the consideration of certain qualitative factors,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company does not currently expect to progress any product candidate through clinical trials or commercial approval and it does not currently expect to generate any revenue from product sales. The Company may never succeed in realizing the value of its intellectual property estate and other assets and, even if it does, it may never generate revenue that is significant or large enough to achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">As a result, the Company may need additional funding to support its operating activities as it seeks to realize value from its intellectual property estate and other assets. Until such time, if ever, that the Company can generate substantial revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If the Company is unable to obtain funding as needed, it may decide to pursue a dissolution and liquidation.</span></p>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-114600000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58200000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275600000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71000000.0
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the pattern and method of recognizing revenue, the accrual of research and development costs, and the annual assessment of impairment of goodwill and in-process research and development assets. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	71000000.0
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	133500000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2800000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	2500000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be creditworthy and the Company has not experienced any losses on these deposits. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company’s cash and cash equivalents were held with one financial institution. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span>
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	18100000
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5053000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.50
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	22000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	861000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18532000
CY2022Q4	fnch	Transfers Between Fair Value Levels TransfersBetweenFairValueLevels	0
CY2021Q4	fnch	Transfers Between Fair Value Levels TransfersBetweenFairValueLevels	0
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25222000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23861000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9286000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4226000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15936000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19635000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5500000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2300000
CY2015Q4	fnch	Lessee Operating Lease Leases Area LesseeOperatingLeaseLeasesArea	25785
CY2021Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The lease term, as assumed, was from March 2021 through February 2023
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32752000
CY2022Q4	fnch	Lease Assets LeaseAssets	32753000
CY2021Q4	fnch	Lease Assets LeaseAssets	5075000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3431000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1128000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	6000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	19000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34255000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4887000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7000
CY2022Q4	fnch	Lease Liabilities LeaseLiabilities	37692000
CY2021Q4	fnch	Lease Liabilities LeaseLiabilities	6041000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	22000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	27000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5230000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1336000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	173000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	254000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1949000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	525000
CY2022	us-gaap	Sublease Income SubleaseIncome	702000
CY2021	us-gaap	Sublease Income SubleaseIncome	88000
CY2022	us-gaap	Lease Cost LeaseCost	6676000
CY2021	us-gaap	Lease Cost LeaseCost	2064000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y2M12D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.306
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.306
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1931000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1006000
CY2022	fnch	Principal Payments On Capital Lease Obligation PrincipalPaymentsOnCapitalLeaseObligation	22000
CY2021	fnch	Principal Payments On Capital Lease Obligation PrincipalPaymentsOnCapitalLeaseObligation	27000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	6103000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	6000
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due Current OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueCurrent	6109000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6255000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	0
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Two Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInTwoYears	6255000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6427000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	0
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Three Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInThreeYears	6427000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	6186000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	0
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Four Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFourYears	6186000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5215000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due In Five Years OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueInFiveYears	5215000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	22390000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due Thereafter OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDueThereafter	22390000
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	52576000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	6000
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Due OperatingAndFinanceLeaseObligationFutureMinimumPaymentsDue	52582000
CY2022Q4	fnch	Interest Portion Of Operating Leases Future Minimum Payments Due InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue	-14890000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	0
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Interest Included In Payments OperatingAndFinanceLeaseObligationFutureMinimumPaymentsInterestIncludedInPayments	-14890000
CY2022Q4	fnch	Present Value Of Future Minimum Lease Payments PresentValueOfFutureMinimumLeasePayments	37686000
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	6000
CY2022Q4	fnch	Operating And Finance Lease Obligation Future Minimum Payments Present Value Of Net Minimum Payments OperatingAndFinanceLeaseObligationFutureMinimumPaymentsPresentValueOfNetMinimumPayments	37692000
CY2022Q4	fnch	Accrued Research And Development AccruedResearchAndDevelopment	1967000
CY2021Q4	fnch	Accrued Research And Development AccruedResearchAndDevelopment	1345000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5852000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1117000
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	880000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4401000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1462000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3062000
CY2022Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	10161000
CY2021Q4	fnch	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	9925000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	574000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	7210000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	7216000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	15000000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	2400000
CY2022Q3	us-gaap	Restructuring Costs RestructuringCosts	200000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	500000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0500
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0690
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0388
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0019
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0212
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2212
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2930
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0053
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	61782000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48419000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6033000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4376000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	17000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	859000
CY2022Q4	fnch	Right Of Use Liabilities RightOfUseLiabilities	10225000
CY2021Q4	fnch	Right Of Use Liabilities RightOfUseLiabilities	1633000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9898000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1310000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	548000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	89265000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	55835000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	75627000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49079000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13638000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6756000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	8057000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	7952000
CY2022Q4	fnch	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	121000
CY2021Q4	fnch	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	563000
CY2022Q4	fnch	Right Of Use Asset RightOfUseAsset	8639000
CY2021Q4	fnch	Right Of Use Asset RightOfUseAsset	1372000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	282000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	330000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	17099000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10217000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3461000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3461000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	26500000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	230900000
CY2022	fnch	Operating Loss Carry Forwards Expiration Year OperatingLossCarryForwardsExpirationYear	2037
CY2022	fnch	Effective Income Tax Rate Reconciliation Tax Credits Research Expiration Date EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate	which will expire at various dates through 2041
CY2021	fnch	Effective Income Tax Rate Reconciliation Tax Credits Research Expiration Date EffectiveIncomeTaxRateReconciliationTaxCreditsResearchExpirationDate	which will expire at various dates through 2041
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1822000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1318000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	651000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	507000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2473000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1822000
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022	us-gaap	Cost Maintenance CostMaintenance	5000000
CY2022Q4	fnch	Commitments And Contingencies Due In Next Twelve Months CommitmentsAndContingenciesDueInNextTwelveMonths	5000000
CY2022Q4	fnch	Commitments And Contingencies Due In Next Second Year CommitmentsAndContingenciesDueInNextSecondYear	20000000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3560471
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3309965
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	500000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0226
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0088
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.87
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7844000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4161000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	800000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-114646000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58160000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-114646000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-114646000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58160000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-58160000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47691632
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47691632
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39202086
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39202086
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.40
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.40
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3560471
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3309965
CY2022	us-gaap	Restructuring And Related Activities Description RestructuringAndRelatedActivitiesDescription	The Company initiated the January 2023 Restructuring on January 24, 2023, with the majority of impacted positions ending in February 2023 and a small number of positions maintained into May 2023.

Files In Submission

Name	View Source	Status
0000950170-23-009490-index-headers.html	Edgar Link	pending
0000950170-23-009490-index.html	Edgar Link	pending
0000950170-23-009490.txt	Edgar Link	pending
0000950170-23-009490-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fnch-20221231.htm	Edgar Link	pending
fnch-20221231.xsd	Edgar Link	pending
fnch-ex10_14.htm	Edgar Link	pending
fnch-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
fnch-20221231_pre.xml	Edgar Link	unprocessable
fnch-20221231_htm.xml	Edgar Link	completed
fnch-ex10_15.htm	Edgar Link	pending
fnch-ex21_1.htm	Edgar Link	pending
fnch-ex23_1.htm	Edgar Link	pending
fnch-ex31_1.htm	Edgar Link	pending
fnch-ex31_2.htm	Edgar Link	pending
fnch-ex32_1.htm	Edgar Link	pending
img103288029_0.jpg	Edgar Link	pending
img144288451_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
fnch-20221231_cal.xml	Edgar Link	unprocessable
fnch-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FNCH
Finch Therapeutics Group, Inc. Stock $fnch

2023 Q1 Form 10-K Financial Statement

#000095017023009490 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FNCH Finch Therapeutics Group, Inc. Stock $fnch

2023 Q1 Form 10-K Financial Statement

#000095017023009490 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FNCH
Finch Therapeutics Group, Inc. Stock $fnch